Iterion Therapeutics Doses First Patient in Colorectal Cancer Trial for Wnt Inhibitor Tegavivint
Mar 25, 2026
Iterion Therapeutics has dosed the first patient in a phase 1/2 trial of its Wnt/β-catenin inhibitor tegavivint for metastatic colorectal cancer. The expansion builds on promising monotherapy activity observed in advanced hepatocellular carcinoma, targeting a pathway activated in over 90% of colorectal cancer patients.